Whereas BRCA1/2 pathogenic variants have been reported in familial pancreatic cancer patients with a prevalence of 0.8% (5/638) to 7.3% (9/124) in large studies (> 100 patients) from the USA and Canada [9, 49, 50]. This evidence concerns the gene BRCA1 and pancreatic neoplasm.